Immunocore (NASDAQ:IMCR – Get Free Report) and CureVac (NASDAQ:CVAC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
Volatility and Risk
Immunocore has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
Institutional & Insider Ownership
84.5% of Immunocore shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 2.1% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunocore | $400.02 million | 3.82 | -$35.51 million | ($0.37) | -80.30 |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
CureVac has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Immunocore and CureVac, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 1 | 4 | 6 | 1 | 2.58 |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
Immunocore presently has a consensus target price of $56.38, indicating a potential upside of 89.75%. Given Immunocore’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunocore is more favorable than CureVac.
Profitability
This table compares Immunocore and CureVac’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -4.20% | -4.54% | -1.66% |
| CureVac | 199.92% | -23.03% | -19.09% |
Summary
Immunocore beats CureVac on 9 of the 15 factors compared between the two stocks.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
